ESMO 2024 | PD-L1 expression concordance between primary and recurrent head and neck cancer
Luigi Lorini, MD, Humanitas Research Hospital, Rozzano, Italy, comments on the findings of the CONCORDL-1 study, which retrospectively analyzes PD-L1 expression concordance between primary and recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Whilst results from the KEYNOTE-048 trial (NCT02358031) highlighted the relevance of PD-L1 Combined Positive Score (CPS) as a predictive biomarker for checkpoint inhibitors, findings from this study showed that clinical-pathological variables had no significant impact on concordance. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
